Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Category: Conferences
-
by Alex Menchaca I recently spoke at the Global IP Convention in Bangalore, India. My presentation concerned lifecycle management strategies used by brand-name companies and some recent legal developments that may be helpful for generic companies responding to those strategies. While at the conference, I sat in on the excellent presentation of Mr. Caleb…
-
American Conference Institute will be holding its popular "Paragraph IV Disputes" conference in San Francisco next week, on December 4-5. I will have the honor of speaking at the conference on a panel addressing "Paragraph IV Strategies for Method of Treatment Patents in View of Recent and Pending Decisions Regarding Inducement and Divided Infringement." The…
-
American Conference Institute will be holding its 13th annual "Maximizing Pharmaceutical Patent Life Cycles" conference in New York City on October 10-11. There have many important developments in pharmaceutical patent law over the last year–from use codes to Myriad to the safe harbor–and this conference will bring you up to speed. The conference agenda includes…
-
FDA has been busy preparing for the day when the first biosimilar application is filed. In February, FDA published three draft guidance documents on biosimilars. In May, FDA held a public hearing on the guidance. And earlier this week, FDA announced biosimilar user fee rates for fiscal year 2013. Patent lawyers have been busy preparing…
-
Marcus Evans Conferences will be holding its "5th Product and Pipeline Enhancement for Generics" conference in Washington, DC, on July 18-19. According to the producer, the conference will help attendees "adopt innovative approaches to strengthen the product pipeline and prepare for regulatory changes to emerge as a global player." The conference chair is Richard Dicicco,…
-
American Conference Institute will be holding a "Hatch-Waxman Boot Camp" conference in San Diego on June 25-26. McAndrews partner Herb Hart will be speaking at the conference on post-grant proceedings under the America Invents Act, and particularly how such proceedings might impact ANDA litigation. The full agenda is as follows: Key Agencies Overview: Understanding the…
-
It's been two years since Congress passed the Biologics Price Competition and Innovation Act, and FDA is still waiting to receive the first biosimilar application. But that doesn't mean progress hasn't been made. FDA issued three draft guidance documents in February, and various companies and industry groups have submitted comments on the guidance (see this…
-
I will have the honor of speaking at American Conference Institute's 6th annual Paragraph IV Disputes conference in New York next month. I'll be part of a panel discussion entitled, "Of Labels, Patents and Use Codes: The Significance and Possible Repercussions of Novo Nordisk v. Caraco to Hatch-Waxman Challenges." The remainder of the agenda includes…
-
American Conference Institute will be holding its 16th Advanced Forum on Life Sciences Collaborative Agreements and M&A in New York on February 27th and 28th. The agenda includes the following presentations: What the America Invents Act means for deal makers and business development strategies Identifying IP red flags that impact the value and success of…
-
American Conference Institute will be holding a conference on "Patent Reform for Life Sciences Companies" in New York, NY, January 31st to February 1st, 2012. According to ACI, this is "the critical industry forum on the Leahy-Smith America Invents Act." The agenda features the following presentations: A keynote address by Robert Stoll, Commissioner for Patents,…
Orange Book Blog 